New Zealand markets open in 8 hours 11 minutes

NRx Pharmaceuticals, Inc. (NRXP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.4650-0.0550 (-2.18%)
As of 09:42AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 26.75M
Enterprise value 32.21M
Trailing P/E 0.48
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.90
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.15

Trading information

Stock price history

Beta (5Y monthly) 1.26
52-week change 3-38.88%
S&P500 52-week change 324.13%
52-week high 37.3300
52-week low 31.9000
50-day moving average 33.0608
200-day moving average 33.7271

Share statistics

Avg vol (3-month) 3365.53k
Avg vol (10-day) 375.6k
Shares outstanding 510.7M
Implied shares outstanding 610.7M
Float 87.81M
% held by insiders 126.67%
% held by institutions 13.52%
Shares short (28 Jun 2024) 4301.67k
Short ratio (28 Jun 2024) 42.6
Short % of float (28 Jun 2024) 43.44%
Short % of shares outstanding (28 Jun 2024) 42.82%
Shares short (prior month 31 May 2024) 4316.18k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 302 Apr 2024

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-118.07%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -24.14M
Net income avi to common (ttm)-25.65M
Diluted EPS (ttm)5.2000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.32M
Total cash per share (mrq)0.12
Total debt (mrq)6.78M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.18
Book value per share (mrq)-1.55

Cash flow statement

Operating cash flow (ttm)-19.24M
Levered free cash flow (ttm)-9.95M